|
|
Vaccine Detail
|
Polyvalent melanoma vaccine |
| Vaccine Information |
- Vaccine Name: Polyvalent melanoma vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: whole cell cancer vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: multiple melanoma-related antigens (NCIT_C1633)
- Immunization Route: Intradermal injection (i.d.)
- Description: This is a cancer vaccine consisting of whole irradiated heterologous melanoma cells which express multiple melanoma-related antigens. Polyvalent melanoma vaccine may stimulate an antitumoral cytotoxic T-cell immune response in the host, resulting in inhibition of tumor cell proliferation and tumor cell death. (NCIT_C1633) Vaccines may make the body build an immune response and kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Interferon alfa-2b may interfere with the growth of tumor cells. Treatment with this combination may help treat melanoma. (NCT00004104)
|
| Host Response |
|
|
| References |
NCIT_C1633: Polyvalent Melanoma Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1633]
NCT00004104: Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma [https://clinicaltrials.gov/study/NCT00004104]
|
|
